文献速递临床试验与 GCP真实世界研究与卫生经济

跨诊断元认知治疗与疾病特异性认知行为治疗对照:随机对照优效性试验研究方案

Transdiagnostic metacognitive therapy compared to disorder-specific cognitive behavioral therapy for anxiety disorders: a study protocol for a randomized controlled superiority trial.
PubMed 文献 · Trials · 2026-10-30

本研究为在瑞典斯德哥尔摩门诊开展的前瞻性、实用性、双臂平行组随机对照优效性试验,计划纳入86名以广泛性焦虑障碍、社交焦虑障碍或创伤后应激障碍为主要诊断的成人,比较跨诊断元认知治疗(tMCT)与疾病特异性认知行为治疗(CBT)的疗效。主要结局为主要诊断的自评症状,次要结局包括临床严重程度、缓解率、抑郁症状、功能损害和生活质量,并在治疗前、治疗后及6个月和12个月随访时评估。试验还探讨治疗效应的潜在中介因素、进行卫生经济学评价并探索患者对治疗的看法。

要点

  • tMCT与疾病特异性CBT的疗效比较尚需充分把握度的研究验证。
  • 主要结局为主要诊断的自评症状,随访至12个月。
  • 试验同时评估中介因素、成本效果和患者视角。

核心结论

  • 本试验旨在研究tMCT相比疾病特异性CBT对焦虑障碍的有效性,并补充tMCT的证据基础。

研究设计与样本

  • 前瞻性、实用性、双臂平行组随机对照优效性试验,在瑞典斯德哥尔摩门诊精神科服务中开展。
  • 计划招募86名成人,主要诊断为广泛性焦虑障碍、社交焦虑障碍或创伤后应激障碍,随机分配至tMCT或CBT。

关键数值与推荐

  • 主要结局为主要诊断的自评症状;次要结局包括临床严重程度、缓解率、抑郁症状、功能损害和生活质量。
  • 结局在治疗前、治疗后以及6个月和12个月随访时评估;潜在中介因素在治疗期间每周测量。

临床怎么用

  • 结果将为tMCT在常规照护中的治疗开发、决策和实施提供证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anxiety disorders are highly prevalent worldwide and are associated with functional impairment, reduced quality of life and high societal costs. With only approximately 50% of patients achieving remission following cognitive behavioral therapy (CBT), the evaluation of other effective treatments is warranted. Studies suggest that metacognitive therapy (MCT) may be more effective than CBT for anxiety disorders. Although transdiagnostic treatment may be beneficial for treatment implementation and dissemination in routine care, there is currently only one adequately powered study comparing transdiagnostic MCT (tMCT) to disorder-specific CBT for anxiety disorders. The main aim of this trial is to investigate the effectiveness of tMCT compared to disorder-specific CBT for anxiety disorders. The trial also aims to investigate potential mediators of treatment effects in tMCT and CBT, to conduct a health economic evaluation and to explore patients' perspectives on the treatments. METHODS: This trial is a prospective, pragmatic, two-arm parallel-group randomized controlled superiority trial comparing tMCT with disorder-specific CBT, conducted in outpatient psychiatric services in Stockholm, Sweden. A sample of 86 adults with a principal diagnosis of generalized anxiety disorder, social anxiety disorder or posttraumatic stress disorder will be recruited and randomly allocated to tMCT or CBT. Primary outcomes are self-rated symptoms of principal diagnosis, and secondary outcomes are clinical severity, remission rates, depressive symptoms, functional impairment and quality of life. Outcomes will be assessed at pre- and post-treatment as well as at 6- and 12-month follow-up. Metacognitions and cognitions as potential mediators will be measured weekly during treatment. Cost-effectiveness of tMCT compared to CBT will be investigated. Semi-structured interviews will be conducted with participants from both conditions. DISCUSSION: Considering the potential of MCT, further research is needed to evaluate its effectiveness compared to CBT, particularly MCT in a transdiagnostic format. Results from this trial will add to the evidence base for tMCT and inform treatment development, decision-making and implementation of effective treatment for anxiety disorders in routine care. TRIAL REGISTRATION: ClinicalTrials.gov NCT06937892. Registered on April 22nd, 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Petersén N, Santoft F, Jayaram-Lindström N, et al. Transdiagnostic metacognitive therapy compared to disorder-specific cognitive behavioral therapy for anxiety disorders: a study protocol for a randomized controlled superiority trial. Trials. 2026. PMID: 42963571. doi:10.1186/s13063-026-10063-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。